May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today Before joining Inversago, Mr.

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV

January 2022 Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker Phase 2 clinical development Metabolic disorders are a global epidemic1 MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation

Equip your research team with expert-led GPCR pharmacology training. Used by discovery scientists across biotech, pharma, and academia. Shared pharmacology discipline for discovery teams. Corner lessons and analysis • Ability to suggest topics relevant to your programs • Access for biotech, pharma Expert-Level Mastery — Advanced Pharmacology Live AMA Sessions with Terry

GPCR was created to break down barriers across academia, biotech, pharma, and CROs—so knowledge, tools including: Academic researchers (PI, postdoc, student) Industry scientists and R&D leaders Biotech and pharma

Maria Waldhoer on why endpoint GPCR assays miss most of what ligands do — and what kinetic pharmacological fingerprints reveal instead. << Back to podcast list Strategic Partner(s) Maria Waldhoer: Pharmacological a driver of drug action AI combined with functional, not only structural, data The academic-to-Big-Pharma-to-biotech InterAx treats GPCR pharmacology the way engineers treat aircraft design: build the mathematical model Waldhoer, CSO of InterAx Biotech 02:19 — From zoology to GPCRs: fate, not choice 06:48 — Academia to Big Pharma